Contents
What ibogaine is
Ibogaine is the main active alkaloid in the root bark of Tabernanthe iboga, a shrub from Central West Africa. In Gabon, iboga is central to the Bwiti spiritual tradition. Most ibogaine used today is purified or made semi-synthetically, usually as ibogaine hydrochloride, which allows more precise dosing than the plant itself.
In the body, ibogaine is converted into noribogaine, mainly by the liver enzyme CYP2D6. Noribogaine stays in the body far longer than ibogaine and is thought to contribute both to the lasting effects and to the long period in which the heart needs to be watched.
At the doses used in treatment settings, the experience lasts a long time, commonly 18 to 36 hours. It often begins with a dreamlike phase in which memories and images come up, followed by a long reflective phase. Nausea and a strong loss of coordination are common, so someone needs to stay with the person throughout.
Ibogaine attracts interest above all because people who use opioids often report that withdrawal symptoms and cravings ease markedly after a single treatment.
What the research shows
The research is promising, but still young. Only two randomised controlled trials of ibogaine for substance use have ever been carried out. Most knowledge comes from observational studies and case series, where outcomes depend strongly on aftercare.
Two recent studies are often cited. In the Netherlands, a hospital study followed opioid-dependent patients through ibogaine treatment under continuous monitoring, focusing on its effects on the heart (Knuijver and colleagues, 2022). At Stanford, 30 veterans with traumatic brain injury received ibogaine together with magnesium at a clinic in Mexico. One month later they reported large improvements in functioning, PTSD, depression and anxiety, and no serious adverse events were reported (Nature Medicine, 2024). That study had no control group, so expectation effects cannot be ruled out.
New, larger trials are being prepared. Texas has committed state funding to clinical trials of ibogaine, Colorado created a research pilot programme in 2026, and the US government has asked its agencies to speed up review. In Europe, ibogaine is not an approved medicine in any country.
A more detailed English-language overview of the evidence is available on ibogaine.info.
The heart: the central risk
Ibogaine's main risk is its effect on the heart. It prolongs the QT interval, the time the heart's chambers need to recharge electrically after each beat. This can lead to a dangerous rhythm disturbance called torsades de pointes. Deaths have occurred, mostly in settings without proper screening or monitoring.
Because noribogaine stays active for a day or more, this risk does not end when the experience fades. In the Dutch hospital study, half of the patients developed a strongly prolonged QT interval (QTc above 500 milliseconds), even under controlled conditions.
Careful providers therefore treat a few things as the minimum:
- a 12-lead ECG and blood tests, including electrolytes and liver function, before treatment
- continuous ECG monitoring during treatment and for at least 24 hours afterwards; a pulse oximeter alone cannot show changes in the QT interval
- a doctor or nurse physically present, with a defibrillator and an emergency plan
Newer protocols add magnesium to reduce the effect on the heart, as in the Stanford study. This is an encouraging development, but not yet a proven guarantee of safety.
If you use opioids
Opioid dependence is the most common reason people look into ibogaine, and it is also where preparation matters most.
- Methadone or buprenorphine: methadone itself prolongs the QT interval, and both stay in the body for a long time. Careful providers arrange a medically supervised switch to a shorter-acting opioid beforehand. Never stop or switch on your own, and discuss any plan with your prescriber.
- Fentanyl: tell any provider openly if you use it, or if your drugs may contain it. It affects how preparation is planned.
- After treatment: tolerance to opioids can drop sharply. Taking a previous usual dose can be fatal. If there is any chance of using again, never use alone, and keep naloxone nearby if it is available to you.
Methadone and buprenorphine are effective, evidence-based treatments. Ibogaine is not a reason to give them up without a plan agreed with your doctor.
Other medication and health
Several medicines and conditions call for extra care or rule treatment out. A responsible provider checks them all before accepting anyone:
- heart conditions, or a personal or family history of rhythm problems or sudden cardiac death
- any medicine that itself prolongs the QT interval (including some antibiotics, antipsychotics and anti-nausea drugs)
- many antidepressants and other psychiatric medicines
- medicines that block the liver enzyme CYP2D6, which can raise ibogaine levels
- significant liver problems
- a personal history of psychosis or bipolar disorder
Never stop prescribed medication on your own to make treatment possible. Talk to the doctor who prescribed it.
In an emergency, call 112 and say what was taken. Fainting, palpitations, a very slow or irregular heartbeat or a seizure after ibogaine always need urgent medical help. The Belgian Poison Centre (Antigifcentrum / Centre Antipoisons) gives advice day and night on 070 245 245.
Legal status in Belgium and beyond
Belgium: ibogaine is on Belgium's list of psychotropic substances. Importing, exporting, manufacturing, possessing, selling, delivering or acquiring it is prohibited without authorisation from the health authorities.
Netherlands: ibogaine is not listed under the Opium Act, so possession is not a criminal offence. It is not an approved medicine, and providers work in a legal grey area with widely varying standards.
Germany: ibogaine is not listed in the narcotics law (Betäubungsmittelgesetz), but it is not an approved medicine either. Doctors cannot treat patients with it outside research.
France: iboga and ibogaine have been classified as narcotics since 2007.
Elsewhere: ibogaine is Schedule I in the United States, where new state-funded research is starting. It is prescription-only in Canada, New Zealand, Australia and South Africa, though not approved for any use. Many people who seek treatment travel to clinics in Mexico or elsewhere.
Bringing ibogaine into Belgium, by post or in luggage, is prohibited. This is general information, not legal advice, and laws change.
Questions to ask a clinic
Most people who receive ibogaine do so at a clinic abroad. A good clinic will welcome these questions and answer them openly:
- Which medical tests do you require beforehand, and who reviews them?
- Is the heart monitored continuously by ECG, and for how long after the dose?
- Is a doctor or nurse physically present throughout, and is there a defibrillator?
- How far away is the nearest hospital, and what is the emergency plan?
- How will my current medication be handled, and who decides?
- Which substance do you use, in what form, and how is the dose determined?
- What support do you offer after I go home?
- Can you give me an itemised written price, including screening and monitoring?
Reasons to be cautious
- no ECG or blood tests before treatment
- monitoring with a pulse oximeter only
- no medical staff present during the night
- a vague answer about your current medication
- guaranteed success rates or promises of a cure
- pressure to book quickly, or a low price with no line for medical screening
Frequently asked questions
Is ibogaine legal in Belgium?
No. Ibogaine is on Belgium's list of psychotropic substances, and importing, possessing, selling or acquiring it is prohibited without authorisation. In the Netherlands and Germany it is not on the narcotics lists, but it is not an approved medicine there either.
Is ibogaine dangerous?
Its main risk is to the heart: ibogaine can cause a serious rhythm disturbance, and deaths have occurred, mostly without proper screening or monitoring. With thorough medical screening, continuous ECG monitoring and medical staff present, that risk is much better managed, though never zero. See the heart.
How long does an ibogaine treatment take?
The acute effects commonly last 18 to 36 hours, followed by a period of tiredness and poor sleep. Because noribogaine stays in the body for days, careful clinics keep people under observation for some time afterwards, and many programmes last from several days to a week.
Can I have ibogaine if I am on methadone?
Not without careful medical preparation. Methadone itself prolongs the QT interval, so careful providers arrange a supervised switch to a shorter-acting opioid beforehand. Never stop or switch on your own; discuss it with your prescriber. See opioids.
What is the difference between iboga, ibogaine and noribogaine?
Iboga is the plant, usually used as dried root bark, whose strength varies. Ibogaine is its main single alkaloid, which can be dosed more precisely. Noribogaine is what the body turns ibogaine into, and it stays active much longer.
Does ibogaine cure addiction?
No treatment does that on its own. Many people report that withdrawal and cravings ease markedly, but lasting results depend on aftercare and support, and relapse is common without them. The research is promising but still limited.
What happens after treatment?
The first days are often hard: poor sleep, tiredness and sometimes low mood are common. Good aftercare is planned before treatment, with a fixed point of contact, support from people at home and, for people who used opioids, a plan for the risk of overdose. Your GP is a good first point of contact.
Sources
- Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction, 2022;117(1):118-128. PubMed Central
- Cherian KN, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 2024. nature.com
- Health Canada. Notice: Prescription Drug List, multiple additions (including ibogaine). 2017. canada.ca
- Colorado General Assembly. HB26-1325, creating an ibogaine research pilot programme. 2026. leg.colorado.gov
- The Texas Tribune. Texas will launch its own clinical trials into ibogaine. 31 March 2026. texastribune.org
- MAPS. Ibogaine Investigator's Brochure, open-access release. 2026. maps.org
- Wikipedia. Legal status of ibogaine by country (Belgium entry, citing the Royal Decree of 22 January 1998 on psychotropic substances). wikipedia.org
- Ibogaine.info. An independent, in-depth English-language resource on ibogaine. ibogaine.info